Skip to main content
Clinical Trials/EUCTR2019-004947-65-ES
EUCTR2019-004947-65-ES
Active, not recruiting
Phase 1

IMPACT ON THE CLINICAL OUTCOMES AND COST-EFFECTIVENESS OF THE ANTIMICROBIAL THERAPEUTIC MONITORING PROGRAM IN CRITICAL PATIENTS

Santiago Grau Cerrato0 sites230 target enrollmentSeptember 1, 2021

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
- Respiratory infections- Urogenital infections - Abdominal infections
Sponsor
Santiago Grau Cerrato
Enrollment
230
Status
Active, not recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
September 1, 2021
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
Santiago Grau Cerrato

Eligibility Criteria

Inclusion Criteria

  • 1\. Patients of both sexes over 18 years of age
  • 2\. Patients admitted to intensive care units with suspected or confirmed bacterial infection of respiratory, urological or abdominal focus
  • 3\. Patients being treated with linezolid, meropenem alone or in combination with each other, for at least 72 hours
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range 160
  • F.1\.3 Elderly (\>\=65 years) yes
  • F.1\.3\.1 Number of subjects for this age range 70

Exclusion Criteria

  • 1\. Pregnant or actively breastfeeding patients.
  • 2\. Patients receiving oral linezolid
  • 3\. Patients undergoing treatment with any renal replacement therapy or extracorporeal support.

Outcomes

Primary Outcomes

Not specified

Similar Trials